Borelli, Beatrice
University of Pisa · Azienda Ospedaliera Universitaria Pisana
3 papers on CoChatORCID 0000-0002-9739-408X
Most cited papers
- Verified
Upfront FOLFOXIRI plus Bevacizumab with or without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial
Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., et al. (2022) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers
Cited by 280
- Verified
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
Borelli, B., Antoniotti, C., Carullo, M., Germani, M. M., Conca, V., & Masi, G. (2022) · Cancers
Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
Cited by 62
- Verified
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
Rossini, D., Boccaccino, A., Sbrana, A., Daniel, F., Borelli, B., Raimondi, A., Santini, D., Conca, V., Tomasello, G., Caponnetto, S., et al. (2021) · ESMO Open
Neutropenia and Cancer InfectionsColorectal Cancer Treatments and Studies
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free